Reduction of Groin Wound Infections After Vascular Surgery by Using an Incision Management System (IMS)

Overview

Comparison of the Prevena™ IMS with the standard wound management method of sterile plaster in vascular surgery patients.

Full Title of Study: “Reduction of Groin Wound Infections After Vascular Surgery in Patients With Risk Factors by the Use a Negative Pressure Wound Incision Management System (KCI Prevena)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2017

Detailed Description

Comparison of the Prevena™ IMS with the standard wound management method of sterile plaster in vascular surgery patients. The aim is to demonstrate that the application of the Prevena™ IMS significantly reduces the incidence of postoperative wound infections. The wound infections will be classified according to Szilagyi. The treatment phase begins following vascular surgery with wound management using either the Prevena™ IMS or a standard wound dressing, depending on the group to which the patient was randomly assigned. It involves a minimum stay of 7 and maximum 10 days in hospital.

Interventions

  • Device: Prevena™ IMS
    • Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system. The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells.
  • Other: sterile plaster dressings
    • standard wound management method of sterile plaster dressings

Arms, Groups and Cohorts

  • Experimental: Prevena™ IMS
    • The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
  • Other: sterile plaster dressings
    • The wound will be treated with the conventional wound management method of sterile plaster dressing.

Clinical Trial Outcome Measures

Primary Measures

  • wound infections
    • Time Frame: 7 days after the surgery
    • The primary objective is the occurrence of inguinal wound infections following surgery. Wound infections will be classified according to Szilagyi.

Secondary Measures

  • length of hospital stay
    • Time Frame: up to 10 days
  • antibiotic therapy
    • Time Frame: up to 30 days
  • revision surgery
    • Time Frame: up to 30 days
  • necessity of alternative wound dressings
    • Time Frame: up to 30 days
  • prolongation of ambulant treatment
    • Time Frame: up to 30 days

Participating in This Clinical Trial

Inclusion Criteria

  • vascular surgery via right or left inguinal approach – nicotine abuse (active or according to medical condition) – risk factors: 1. cardiac risk factors (arterial hypertension, coronary heart disease, status after myocardial infarction) 2. metabolic disorders (diabetes mellitus type I type II, lipopathy or hyperhomocysteinemia) or chronic or acute renal insufficiency – previous vascular surgery with inguinal approach – signed informed consent form – persons who are legally competent and mentally able to comprehend and follow the instructions of study personnel Exclusion Criteria:

  • local skin infections (fungal infections, acne) – pregnant and breast-feeding women – simultaneous participation in another clinical trial – persons who have been committed to an institution by court or administrative order – persons in a dependency or employment relationship with the sponsor or investigator

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • RWTH Aachen University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jochen Grommes, Principal Investigator, University Hospital, Aachen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.